Clinical Trials
138 trialsCancer in Patients on Dapagliflozin and Other Antidiabetic Treatment
AstraZeneca
TraveraRTGx
Travera Inc
ESPERANZA: External Control Arm Study for T-DXd for Patients With HER2 IHC3+ Solid Tumors
AstraZeneca
AVENANCE
Pfizer
VISIOCYT2
Institut Paoli-Calmettes
GreenBladder - Early Detection of Bladder Cancer in Residents in Greenland Using a Urinary Marker and a Mobile Cystoscopy Unit
Aarhus University Hospital
QSCO
University Hospital, Toulouse
Remote Telemonitoring of Patient-Generated Physiologic Health Data and Patient-Reported Outcomes
City of Hope Medical Center
ctDNA in Subjects With Muscle-invasive Bladder Cancer Treated With Trimodality Therapy
UNC Lineberger Comprehensive Cancer Center
Development of Multiphasic CT-based Delta-Radiomics Model for Predicting Postoperative Recurrence Risk in Bladder Cancer
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
TEP-Vessie
Institut Bergonié
Clinical Registry for Oligometastic Disease, Consolidation Therapy, Debulking Prior to Chemotherapy, or Re-Irradiation
University of Texas Southwestern Medical Center
Decision Making for Urinary Diversion in Patients With Bladder Cancer
University of Colorado, Denver
DELFI-L101
Delfi Diagnostics Inc.
HER2 and LA/mUC: A Multi-country Chart Review Cohort Study
Seagen Inc.
BoBCaT
University Hospital, Rouen
IEPBR
Ankara Etlik City Hospital
CD155 in Bladder Cancer
Fudan University
Brazilian Reality of Urinary Bladder Cancers - BRA-BLADDER
AstraZeneca
Genomic Testing and Resulting Medical Decisions
Arbeitsgemeinschaft medikamentoese Tumortherapie
PREVAILctDNA
Royal Marsden NHS Foundation Trust
A Study of Real-world Treatment of Adults With Urothelial Cancer in South Korea and Saudi Arabia
Astellas Pharma Inc
EPRIMM
The Christie NHS Foundation Trust
Physical Therapy in Pre-cystectomy Patients
UNC Lineberger Comprehensive Cancer Center
QLB-CYS
Namik Kemal University
SNUGGLE
Bristol-Myers Squibb
ROOT
Taproot Health
Mood Disorders Bladder Cancer
University of Kansas Medical Center
ENPP1-BC
Lanzhou University Second Hospital
Resiliency in Patients Undergoing Radical Cystectomy for Bladder Cancer
University of Kansas Medical Center
AURA
UNC Lineberger Comprehensive Cancer Center
Trimodality Treatment in Bladder Cancer
Consorci Sanitari de Terrassa
Evaluating Sexual Function in Women Undergoing a Radical Cystectomy for Bladder Cancer
Mayo Clinic
RADIANT
DxTerity Diagnostics
The Efficacy of Radiomics to Predict Tumor Microenvironment Markers and Comprehensive Therapy for Bladder Cancer
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
The Impact of Neoadjuvant Chemotherapy on Survival Outcomes in Patients With Variant Histologies Bladder Cancer Who Underwent Radical Cystectomy
Ankara Etlik City Hospital
Urine VOC Investigation in Bladder Cancer Diagnosis
First Affiliated Hospital Xi'an Jiaotong University
VI-RADS
Istituto Nazionale di Ricovero e Cura per Anziani
POLARIS
AstraZeneca
Biomarkers of Recurrence and Progression in Non-muscle Invasive Bladder Cancer
Wroclaw Medical University
SOLUSION
Zealand University Hospital
START
University of Trieste
Research on the Accurate Diagnosis of Urinary Tract Tumors and the Development of Kits
Zhongnan Hospital
DETECT I
University College, London
Patterns of Urinary Bladder Cancer in Darfur, Suda
National Center for Gastroentestinal and Liver Disease
DETECT II
University College, London
RESECT
British Urology Researchers in Surgical Training
Neutrophil-to-Lymphocyte Ratio in Bladder Cancer: A Secondary Biomarker Analysis of SWOG 8710
Abramson Cancer Center at Penn Medicine
Anticoagulant/Antiaggregant Use and Postoperative Bleeding Risk in Patients With Bladder Tumor and Benign Prostatic Hyperplasia
Bezmialem Vakif University
Neutrophils to Lymphocytes Ratio in Predicting the Response to BCG in Non-muscle Invasive Bladder Cancer
Ain Shams University